8-K: Anteris Adjourns Special Stockholder Meeting

Anteris Technologies Global Corp. has adjourned its Special Meeting of Stockholders due to a lack of quorum, rescheduling it for September 29, 2025.

Summary

• Anteris Technologies Global Corp. adjourned its Special Meeting of Stockholders, originally convened on September 18, 2025, due to a lack of the required quorum.
• The meeting has been rescheduled for Monday, September 29, 2025, at 8:00 a.m. Central time (11:00 p.m. AEST on Monday, September 29, 2025), and will be held virtually.
• The purpose of the meeting is to vote on proposals, including the ASX Waiver Proposal, which seeks approval for a waiver from ASX Listing Rule 7.1 to permit the Company to issue new securities without obtaining further stockholder approval under that rule.
• The record date for the Special Meeting, August 11, 2025, remains unchanged and applies to the adjourned meeting.
• The Board of Directors unanimously recommends voting FOR the proposals identified in the Company's Proxy Statement.

Sentiment

Score: 4

Explanation: The adjournment due to lack of quorum is a negative administrative event, indicating potential shareholder apathy or disengagement. However, the board's unanimous recommendation for the proposals and the rescheduling of the meeting provide a clear path forward, mitigating some of the negative impact. The underlying business (structural heart devices) is not directly impacted by this administrative delay, but the delay in approving the ASX waiver could be seen as a minor setback for future flexibility.

Positives

• The Board of Directors unanimously recommends that stockholders vote FOR the proposals identified in the Proxy Statement, indicating management's confidence in the proposed actions.
• The company has provided clear instructions and extended deadlines for stockholders to cast their votes, facilitating participation in the rescheduled meeting.

Negatives

• The Special Meeting of Stockholders was adjourned due to a lack of the required quorum, indicating insufficient stockholder engagement or participation on the initial attempt.
• The delay postpones the approval of key proposals, including the ASX Waiver Proposal, which could impact the company's operational flexibility or future strategic initiatives.

Risks

• Uncertainties related to the presence of a quorum at the adjourned Special Meeting.
• Uncertainties regarding the receipt of stockholder approval for the proposals presented at the Special Meeting.
• General risks described under "Risk Factors" in Anteris' Annual Report on Form 10-K filed with the SEC on March 12, 2025 (as amended April 29, 2025) and Quarterly Reports on Form 10-Q filed with the SEC on May 13, 2025, and August 11, 2025.

Future Outlook

The company acknowledges uncertainties related to achieving a quorum at the adjourned Special Meeting and securing stockholder approval for the proposals. It does not assume any obligation to update forward-looking statements except as required by law.

Management Comments

• The Company's Board of Directors unanimously recommends that you vote FOR the proposals identified in the Company's Proxy Statement.

Industry Context

Anteris Technologies Global Corp. operates in the structural heart medical device industry, focusing on innovative solutions like the DurAVR Transcatheter Heart Valve (THV) for aortic stenosis. This administrative filing does not directly impact broader industry trends but is crucial for the company's internal governance and potential strategic flexibility within this competitive sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Required to re-engage and vote on proposals, potentially facing inconvenience due to the adjournment. The delay in approving the ASX waiver could impact future share dilution or capital raise opportunities.
• Management/Board: Faces the challenge of re-soliciting votes and ensuring quorum for the rescheduled meeting, potentially diverting resources.

Next Steps

• Stockholders are urged to vote on the proposals before the new deadlines.
• The adjourned Special Meeting will be held virtually on September 29, 2025.
• The company will continue to solicit proxies for the proposals.

Key Dates

Recommendation

The filing primarily concerns an administrative delay in a shareholder meeting due to a lack of quorum, which is a minor negative. However, the underlying business operations and strategic direction, particularly regarding the DurAVR THV, are not directly impacted by this event. The board's unanimous recommendation for the proposals suggests confidence in the company's path. Investors should hold to observe the outcome of the rescheduled meeting and any subsequent strategic announcements, as the core value proposition remains unchanged by this procedural issue.

Keywords

Anteris Technologies, AVR, ASX, NASDAQ, Special Meeting, Stockholders, Quorum, Adjournment, Proxy Statement, Corporate Governance, Medical Devices, Structural Heart, DurAVR, ADAPT tissue, Aortic Stenosis, ASX Listing Rule 7.1, Shareholder Vote